Drugs / Flu/COVm
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07464314 | Mar → Dec 2026 expected | influenza | GlaxoSmithKline | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flu/COVm | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07464314 ↗ |
| Known as | Flu/COVm Vaccine | “Flu/COVm Vaccine with multiple dose levels (Dose Level 1, Dose Level 2, and Dose Level 3), will be administered via single intramuscular injection.” NCT07464314 ↗ |
| Modality | Messenger RNA (mRNA) | “new mRNA vaccine” NCT07464314 ↗ |
| Route | Intramuscular | “single intramuscular injection” NCT07464314 ↗ |